| scholarly article | Q13442814 |
| P8978 | DBLP publication ID | journals/nar/KantorMGDSS01 |
| P356 | DOI | 10.1093/NAR/29.1.296 |
| P932 | PMC publication ID | 29795 |
| P698 | PubMed publication ID | 11125118 |
| P5875 | ResearchGate publication ID | 12204008 |
| P2093 | author name string | Shafer RW | |
| Schapiro JM | |||
| Kantor R | |||
| Machekano R | |||
| Dupnik K | |||
| Gonzales MJ | |||
| P2860 | cites work | Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry | Q29620710 |
| Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel | Q33824632 | ||
| Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries | Q36971551 | ||
| Human immunodeficiency virus reverse transcriptase and protease sequence database | Q39541777 | ||
| Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database | Q39726646 | ||
| Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. | Q43797586 | ||
| HIV-1 nomenclature proposal | Q48750867 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | data model | Q1172480 |
| natural language | Q33742 | ||
| P304 | page(s) | 296-299 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Nucleic Acids Research | Q135122 |
| P1476 | title | Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs | |
| P478 | volume | 29 |
| Q35742512 | A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies |
| Q39743833 | A genotyping study of human immunodeficiency virus type-1 drug resistance in a small Brazilian municipality. |
| Q28469157 | A look inside HIV resistance through retroviral protease interaction maps |
| Q33247450 | Adaptation to different human populations by HIV-1 revealed by codon-based analyses |
| Q57167106 | Antiretroviral resistance in HIV-1 patients at a tertiary medical institute in Saudi Arabia: a retrospective study and analysis |
| Q39913681 | Binding modes of two novel non-nucleoside reverse transcriptase inhibitors, YM-215389 and YM-228855, to HIV type-1 reverse transcriptase |
| Q28539169 | Comparable long-term efficacy of Lopinavir/Ritonavir and similar drug-resistance profiles in different HIV-1 subtypes |
| Q44078237 | Comparison of virtual phenotype and HIV-SEQ program (Stanford) interpretation for predicting drug resistance of HIV strains. |
| Q47447715 | Covariation of amino acid positions in HIV-1 protease |
| Q36529238 | Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity |
| Q42248267 | Direct monthly highly active antiretroviral therapy supply - a method to increase patient's adherence and outcome. Experience of one AIDS centre in Israel |
| Q37197054 | Directly administered antiretroviral therapy for HIV-infected drug users does not have an impact on antiretroviral resistance: results from a randomized controlled trial |
| Q30762478 | Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms |
| Q35667018 | Drug resistance in non-subtype B HIV-1. |
| Q44615578 | Emerging trends of drug-resistant HIV-1 among drug-treated patients in former blood donors in Hubei, China: a three-year surveillance from 2004 to 2006. |
| Q33648513 | Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape |
| Q46891926 | Estimation of an in vivo fitness landscape experienced by HIV-1 under drug selective pressure useful for prediction of drug resistance evolution during treatment |
| Q45736222 | Extent of human immunodeficiency virus type 1 drug resistance as a predictor of virological failure after genotype-guided treatment switch |
| Q33906239 | Genotypic testing for human immunodeficiency virus type 1 drug resistance |
| Q35182711 | HIV sequence databases |
| Q41765940 | HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy |
| Q29616403 | Human immunodeficiency virus reverse transcriptase and protease sequence database |
| Q34253401 | Investigation of Super Learner Methodology on HIV-1 Small Sample: Application on Jaguar Trial Data |
| Q37961181 | Mechanism of HIV antiretroviral drugs progress toward drug resistance |
| Q34140913 | Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir |
| Q40469287 | Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1 |
| Q34342200 | Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure |
| Q28284852 | Patient-specific simulation as a basis for clinical decision-making |
| Q82307179 | Phenotypic analysis of HIV-1 genotypic drug-resistant isolates from China, using a single-cycle system |
| Q38879828 | Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections |
| Q33199293 | Purifying selection masks the mutational flexibility of HIV-1 reverse transcriptase |
| Q36102542 | Sequence quality analysis tool for HIV type 1 protease and reverse transcriptase |
| Q37018369 | The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors. |
| Q28487475 | Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy |
| Q43586569 | Universal profiling of HIV-1 pol for genotypic study and resistance analysis across subtypes |
| Q39477972 | Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nuleoside analogs |
Search more.